JOURNAL OF COSMETIC SCIENCE 436 (12) H. H. L o h, L. F. Tseng, E. Wei, and C. H. Li, Beta-endorphin is a potent analgesic agent, Proc. Natl. Acad. Sci. U.S.A., 73, 2895–2898 (1976). (13) H. Qian, J. Yi, J. Zhou, Y. Zhao, Y. Li, Z. Jin, and Y. Ding, Activation of cannabinoid receptor CB2 regulates LPS-induced pro-infl ammatory cytokine production and osteoclastogenic gene expression in human periodontal ligament cells, Open J. Stomatol., 3, 44–51 (2013). (14) S. Ständ e r, C. Moormann, M. Schumacher, J. Buddenkotte, M. Artuc, V. Shpacovitch, T. Brzoska, U. Lippert, B. M. Henz, T. A. Luger, D. Metze, and M. Steinhoffand, Expression of vanilloid receptor sub- type 1 in cutaneous sensory nerve fi bers, mast cells, and epithelial cells of appendage structures, Exp. Dermatol., 13, 129–139 (2004). (15) M. Denda, S. Fuziwara, K. Inoue, S. Denda, H. Akamatsu, A. Tomitaka, and K. Matsunaga, Immuno- reactivity of VR1 on epidermal keratinocyte of human skin, Biochem. Biophys. Res. Commun., 285, 1250– 1252 (2001). (16) E. Bodó, T . Bíró, A. Telek, G. Czifra, Z. Griger, B. I. Tóth, A. Mescalchin, T. Ito, A. Bettermann, L. Kovács, and R. Paus, A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/ TRPV1) signaling in human hair growth control, Am. J. Pathol., 166, 985–998 (2005). (17) B. I. Tóth, S. Benk o , A. G. Szöllosi, L. Kovács, E. Rajnavölgyi, and T. Bíró, Transient receptor potential vanilloid-1 signaling inhibits differentiation and activation of human dendritic cells, FEBS Lett., 583, 1619–1924 (2009). (18) Y. M. Lee, Y. K. Kim, and J. H. Chung, Increased expression of TRPV1 channel in intrinsically aged and photoaged human skin in vivo, Exp. Dermatol., 18, 431–436 (2009). (19) Y. M. Lee, S. M. Kang, an d J. H. Chung, The role of TRPV1 channel in aged human skin, J. Dermatol. Sci., 65, 81–85 (2012). (20) S. A. Bonini, M. Premoli, S. Tambaro, A. Kumar, G. Maccarinelli, M. Memo, and A. Mastinun, Can- nabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history, J. Ethnopharmacol., 227, 300–315 (2018). (21) K. Fidyt, A. Fiedorowicz, L. Strządala, and A. Szumny, β-caryophyllene and β-caryophyllene oxide- natural compounds of anticancer and analgesic properties, Cancer Med., 5, 3007–3017 (2016). (22) V. Di Marzo and F. Piscitelli, The endocannabinoid system and its modulation by phytocannabinoids, Neurotherapeutics, 12, 692–698 (2015). (23) Y. Xian, J. Suo, X. D. Huang, S . Z. Hou, J. N. Chen, M. R. Ye, and Z. R. Su, A pharmacological study on anti-infl ammatory effects of refi ned Huodan recipe, Chin. J. Exp. Tradit. Med. Formul., 13, 54–56 (2007). (24) S. C. Zhao, Q. Jia, and F. L. Li a o, The anti-infl ammatory and analgesic pharmacological study of Patchouli extract, Chin Tradit Pat Med., 29, 285–287 (2007). (25) M. K. Swamy and U. R. Sinniah, A c omprehensive review on the phytochemical constituents and phar- macological activities of Pogostemon cablin benth.: an aromatic medicinal plant of industrial importance, Molecules, 20, 8521–8547 (2015). (26) H. S. Kusuma and M. Mahfuda, The ex traction of essential oils from patchouli leaves (Pogostemon cablin Benth) using a microwave air-hydrodistillation method as a new green technique, RSC Adv., 7, 1336– 1347 (2017). (27) A. Oláh and T. Bíró, Targeting cuta n eous cannabinoid signaling in infl ammation - a “high”-way to heal? EBioMedicine, 16, 3–5 (2017). (28) S. Ghosh, L. E. Wise, Y. Chen, R. Gujjar, A. Mahadevan, B. F. Cravatt, and A. H. Lichtman, The mono- acylglycerol li p ase inhibitor JZL184 suppresses infl ammatory pain in the mouse carrageenan model, Life Sci., 92, 498–505 (2013). (29) J. C. Ashton and M. Glass, The cannabinoid CB2 receptor as a target for infl ammation-dependent neu- rodegeneration, C u rr. Neuropharmacol., 5, 73–80 (2007). (30) N. D. Berger, V. M. Gadotti, R. R. Petrov, K. Chapman, P. Diaz, and G. W. Zamponi, NMP-7 inhibits chronic infl ammato r y and neuropathic pain via block of Cav3.2 T-type calcium channels and activation of CB2 receptors, Mol. Pain, 10, 77 (2014). (31) A. Quartilho, H. P. Mata, M. M. Ibrahim, T. W. Vanderah, F. Porreca, A. Makriyannis, and T. P. Malan, Jr., Inhibitio n of infl ammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors, Anesthesiology, 99, 955–960 (2003). (32) B. B. Yao, G. C. Hsieh, J. M. Frost, Y. Fan, T. R. Garrison, A. V. Daza, G. K. Grayson, C. Z. Zhu, M. Pai, P. Chandra n , A. K. Salyers, E. J. Wensink, P. Honore, J. P. Sullivan, M. J. Dart, and M. D. Meyerand, In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibit- ing analgesic activity in rodent pain models, Br. J. Pharmacol., 153, 390–401 (2008).

SOOTHING EFFECT OF POGOSTEMON CABLIN EXTRACT 437 (33) M. M. Ibrahim, F. Porreca, J. Lai, P. J. Albrecht, F. L. Rice, A. Khodorova, G. Davar, A. Makriyannis, T. W. Vanderah, H. P. Mata, and T. Philip Malan, Jr., CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. U.S.A., 102, 3093–3098 (2005). (34) J. G. Bonchak and R. A. Swerlick, Emerging therapies for atopic dermatitis: TRPV1 antagonists. J. Am. Acad. Dermatol., 7 8(Suppl. 1), S63–S66 (2018).